{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:20:01Z","timestamp":1786558801811,"version":"build-2736575974"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40263-025-01238-9","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:10Z","timestamp":1762505410000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New and Emerging Therapies for Patients with Low-Grade Glioma"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-3868","authenticated-orcid":false,"given":"Katherine B.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"6892","key":"1238_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"2","key":"1238_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nox141","volume":"20","author":"DTW Jones","year":"2018","unstructured":"Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20(2):160\u201373. https:\/\/doi.org\/10.1093\/neuonc\/nox141.","journal-title":"Neuro Oncol"},{"key":"1238_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011254","author":"DK Morrison","year":"2012","unstructured":"Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol. 2012. https:\/\/doi.org\/10.1101\/cshperspect.a011254.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1238_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060794","author":"F Behling","year":"2019","unstructured":"Behling F, Schittenhelm J. Oncogenic BRAF alterations and their role in brain tumors. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11060794.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"1238_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1634\/theoncologist.2017-0242","volume":"22","author":"A Johnson","year":"2017","unstructured":"Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22(12):1478\u201390. https:\/\/doi.org\/10.1634\/theoncologist.2017-0242.","journal-title":"Oncologist"},{"issue":"4","key":"1238_CR6","doi-asserted-by":"publisher","first-page":"569.e5","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569.e5-583.e5. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.011.","journal-title":"Cancer Cell"},{"issue":"9","key":"1238_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/NEN.0b013e3181845622","volume":"67","author":"EE Bar","year":"2008","unstructured":"Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67(9):878\u201387. https:\/\/doi.org\/10.1097\/NEN.0b013e3181845622.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"1238_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","volume":"129","author":"VP Collins","year":"2015","unstructured":"Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):775\u201388. https:\/\/doi.org\/10.1007\/s00401-015-1410-7.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"1238_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/nen.0000000000000226","volume":"74","author":"C Faulkner","year":"2015","unstructured":"Faulkner C, Ellis HP, Shaw A, Penman C, Palmer A, Wragg C, et al. BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15\u20139 fusions are more frequent in the midline than within the cerebellum. J Neuropathol Exp Neurol. 2015;74(9):867\u201372. https:\/\/doi.org\/10.1097\/nen.0000000000000226.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"1238_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/path.2558","volume":"218","author":"T Forshew","year":"2009","unstructured":"Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, et al. Activation of the ERK\/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218(2):172\u201381. https:\/\/doi.org\/10.1002\/path.2558.","journal-title":"J Pathol"},{"issue":"21","key":"1238_CR11","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1158\/0008-5472.Can-08-2097","volume":"68","author":"DT Jones","year":"2008","unstructured":"Jones DT, Kocialkowski S, Liu L, Pearson DM, B\u00e4cklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-2097.","journal-title":"Cancer Res"},{"issue":"3","key":"1238_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1750-3639.2008.00225.x","volume":"19","author":"AJ Sievert","year":"2009","unstructured":"Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449\u201358. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00225.x.","journal-title":"Brain Pathol"},{"issue":"14","key":"1238_CR13","first-page":"3955","volume":"63","author":"A Gorden","year":"2003","unstructured":"Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63(14):3955\u20137.","journal-title":"Cancer Res"},{"issue":"20","key":"1238_CR14","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/onc.2009.73","volume":"28","author":"DT Jones","year":"2009","unstructured":"Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 2009;28(20):2119\u201323. https:\/\/doi.org\/10.1038\/onc.2009.73.","journal-title":"Oncogene"},{"issue":"8","key":"1238_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373. https:\/\/doi.org\/10.1056\/NEJMoa0808710.","journal-title":"N Engl J Med"},{"issue":"2","key":"1238_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ijc.24379","volume":"125","author":"MR Kang","year":"2009","unstructured":"Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125(2):353\u20135. https:\/\/doi.org\/10.1002\/ijc.24379.","journal-title":"Int J Cancer"},{"issue":"5897","key":"1238_CR17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807\u201312. https:\/\/doi.org\/10.1126\/science.1164382.","journal-title":"Science"},{"issue":"2","key":"1238_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","volume":"34","author":"MS Waitkus","year":"2018","unstructured":"Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018;34(2):186\u201395. https:\/\/doi.org\/10.1016\/j.ccell.2018.04.011.","journal-title":"Cancer Cell"},{"issue":"20","key":"1238_CR19","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.Ccr-12-1773","volume":"18","author":"H Yang","year":"2012","unstructured":"Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562\u201371. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-1773.","journal-title":"Clin Cancer Res"},{"issue":"7274","key":"1238_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344. https:\/\/doi.org\/10.1038\/nature08617.","journal-title":"Nature"},{"issue":"8","key":"1238_CR21","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1073\/pnas.1019393108","volume":"108","author":"ZJ Reitman","year":"2011","unstructured":"Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA. 2011;108(8):3270\u20135. https:\/\/doi.org\/10.1073\/pnas.1019393108.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1238_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","volume":"12","author":"R Chowdhury","year":"2011","unstructured":"Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463\u20139. https:\/\/doi.org\/10.1038\/embor.2011.43.","journal-title":"EMBO Rep"},{"issue":"1","key":"1238_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.014.","journal-title":"Cancer Cell"},{"issue":"5","key":"1238_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/neuonc\/nox183","volume":"20","author":"TM Malta","year":"2018","unstructured":"Malta TM, de Souza CF, Sabedot TS, Silva TC, Mosella MS, Kalkanis SN, et al. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol. 2018;20(5):608\u201320. https:\/\/doi.org\/10.1093\/neuonc\/nox183.","journal-title":"Neuro Oncol"},{"issue":"7390","key":"1238_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","volume":"483","author":"S Turcan","year":"2012","unstructured":"Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479\u201383. https:\/\/doi.org\/10.1038\/nature10866.","journal-title":"Nature"},{"issue":"26","key":"1238_CR26","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1402121.","journal-title":"N Engl J Med"},{"issue":"3","key":"1238_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550\u201363. https:\/\/doi.org\/10.1016\/j.cell.2015.12.028.","journal-title":"Cell"},{"issue":"26","key":"1238_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499\u2013508. https:\/\/doi.org\/10.1056\/NEJMoa1407279.","journal-title":"N Engl J Med"},{"issue":"1","key":"1238_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12325-021-01977-3","volume":"39","author":"V Di Nunno","year":"2022","unstructured":"Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, et al. Clinical and molecular features of patients with gliomas harboring IDH1 non-canonical mutations: a systematic review and meta-analysis. Adv Ther. 2022;39(1):165\u201377. https:\/\/doi.org\/10.1007\/s12325-021-01977-3.","journal-title":"Adv Ther"},{"issue":"4","key":"1238_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","volume":"118","author":"C Hartmann","year":"2009","unstructured":"Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469\u201374. https:\/\/doi.org\/10.1007\/s00401-009-0561-9.","journal-title":"Acta Neuropathol"},{"issue":"25","key":"1238_CR31","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/jco.2009.21.9832","volume":"27","author":"M Sanson","year":"2009","unstructured":"Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150\u20134. https:\/\/doi.org\/10.1200\/jco.2009.21.9832.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1238_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1634\/theoncologist.2015-0342","volume":"21","author":"AT Fathi","year":"2016","unstructured":"Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, et al. Elevation of urinary 2-hydroxyglutarate in IDH-mutant glioma. Oncologist. 2016;21(2):214\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2015-0342.","journal-title":"Oncologist"},{"key":"1238_CR33","doi-asserted-by":"publisher","first-page":"1067252","DOI":"10.3389\/fonc.2022.1067252","volume":"12","author":"V Di Nunno","year":"2022","unstructured":"Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E. Implications of BRAF V600E mutation in gliomas: molecular considerations, prognostic value and treatment evolution. Front Oncol. 2022;12:1067252. https:\/\/doi.org\/10.3389\/fonc.2022.1067252.","journal-title":"Front Oncol"},{"issue":"3","key":"1238_CR34","doi-asserted-by":"publisher","first-page":"Cns39","DOI":"10.2217\/cns-2019-0009","volume":"8","author":"N Shaikh","year":"2019","unstructured":"Shaikh N, Brahmbhatt N, Kruser TJ, Kam KL, Appin CL, Wadhwani N, et al. Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol. 2019;8(3):Cns39. https:\/\/doi.org\/10.2217\/cns-2019-0009.","journal-title":"CNS Oncol."},{"key":"1238_CR35","doi-asserted-by":"publisher","first-page":"1071314","DOI":"10.3389\/fnins.2022.1071314","volume":"16","author":"M Xie","year":"2022","unstructured":"Xie M, Wang X, Duan Z, Luan G. Low-grade epilepsy-associated neuroepithelial tumors: tumor spectrum and diagnosis based on genetic alterations. Front Neurosci. 2022;16:1071314. https:\/\/doi.org\/10.3389\/fnins.2022.1071314.","journal-title":"Front Neurosci"},{"issue":"1","key":"1238_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0125-9","volume":"5","author":"HL M\u00fcller","year":"2019","unstructured":"M\u00fcller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. https:\/\/doi.org\/10.1038\/s41572-019-0125-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1238_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11912-020-01006-6","volume":"23","author":"A Dono","year":"2021","unstructured":"Dono A, Ballester LY, Primdahl D, Esquenazi Y, Bhatia A. IDH-mutant low-grade glioma: advances in molecular diagnosis, management, and future directions. Curr Oncol Rep. 2021;23(2):20. https:\/\/doi.org\/10.1007\/s11912-020-01006-6.","journal-title":"Curr Oncol Rep"},{"key":"1238_CR38","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1016\/j.wneu.2017.12.112","volume":"111","author":"K Phan","year":"2018","unstructured":"Phan K, Ng W, Lu VM, McDonald KL, Fairhall J, Reddy R, et al. Association between IDH1 and IDH2 mutations and preoperative seizures in patients with low-grade versus high-grade glioma: a systematic review and meta-analysis. World Neurosurg. 2018;111:e539\u201345. https:\/\/doi.org\/10.1016\/j.wneu.2017.12.112.","journal-title":"World Neurosurg."},{"issue":"19","key":"1238_CR39","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/wnl.0000000000003911","volume":"88","author":"H Chen","year":"2017","unstructured":"Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017;88(19):1805\u201313. https:\/\/doi.org\/10.1212\/wnl.0000000000003911.","journal-title":"Neurology"},{"issue":"21","key":"1238_CR40","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/wnl.0000000000012893","volume":"97","author":"M Ohno","year":"2021","unstructured":"Ohno M, Hayashi Y, Aikawa H, Hayashi M, Miyakita Y, Takahashi M, et al. Tissue 2-hydroxyglutarate and preoperative seizures in patients with diffuse gliomas. Neurology. 2021;97(21):e2114\u201323. https:\/\/doi.org\/10.1212\/wnl.0000000000012893.","journal-title":"Neurology"},{"key":"1238_CR41","doi-asserted-by":"crossref","unstructured":"Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT. CBTRUS statistical report: Pediatric Brain Tumor Foundationchildhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol. 2025;15;27(Supplement_1):i1-i42.","DOI":"10.1093\/neuonc\/noaf168"},{"key":"1238_CR42","doi-asserted-by":"publisher","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol. 2024;26(Supplement_6):vi1-vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","DOI":"10.1093\/neuonc\/noae145"},{"issue":"4","key":"1238_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.23736\/s0390-5616.19.04701-5","volume":"63","author":"RA Morshed","year":"2019","unstructured":"Morshed RA, Young JS, Hervey-Jumper SL, Berger MS. The management of low-grade gliomas in adults. J Neurosurg Sci. 2019;63(4):450\u20137. https:\/\/doi.org\/10.23736\/s0390-5616.19.04701-5.","journal-title":"J Neurosurg Sci"},{"issue":"1","key":"1238_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-015-1961-4","volume":"126","author":"PA Bonney","year":"2016","unstructured":"Bonney PA, Boettcher LB, Conner AK, Glenn CA, Briggs RG, Santucci JA, et al. Review of seizure outcomes after surgical resection of dysembryoplastic neuroepithelial tumors. J Neurooncol. 2016;126(1):1\u201310. https:\/\/doi.org\/10.1007\/s11060-015-1961-4.","journal-title":"J Neurooncol"},{"issue":"1","key":"1238_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3171\/jns.2006.104.1.62","volume":"104","author":"CH Chan","year":"2006","unstructured":"Chan CH, Bittar RG, Davis GA, Kalnins RM, Fabinyi GC. Long-term seizure outcome following surgery for dysembryoplastic neuroepithelial tumor. J Neurosurg. 2006;104(1):62\u20139. https:\/\/doi.org\/10.3171\/jns.2006.104.1.62.","journal-title":"J Neurosurg"},{"issue":"1","key":"1238_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ons\/opz336","volume":"19","author":"AK Almekkawi","year":"2020","unstructured":"Almekkawi AK, El Ahmadieh TY, Wu EM, Abunimer AM, Abi-Aad KR, Aoun SG, et al. The use of 5-aminolevulinic acid in low-grade glioma resection: a systematic review. Oper Neurosurg. 2020;19(1):1\u20138. https:\/\/doi.org\/10.1093\/ons\/opz336.","journal-title":"Oper Neurosurg"},{"issue":"1","key":"1238_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neurad.2019.08.005","volume":"48","author":"M Edjlali","year":"2021","unstructured":"Edjlali M, Ploton L, Maurage CA, Delmaire C, Pruvo JP, Reyns N, et al. Intraoperative MRI and FLAIR analysis: implications for low-grade glioma surgery. J Neuroradiol. 2021;48(1):61\u20134. https:\/\/doi.org\/10.1016\/j.neurad.2019.08.005.","journal-title":"J Neuroradiol"},{"issue":"11","key":"1238_CR48","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/jco.21.02929","volume":"41","author":"SL Hervey-Jumper","year":"2023","unstructured":"Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, et al. Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. J Clin Oncol. 2023;41(11):2029\u201342. https:\/\/doi.org\/10.1200\/jco.21.02929.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1238_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1227\/NEU.0b013e31822ff0ed","volume":"70","author":"H Ogiwara","year":"2012","unstructured":"Ogiwara H, Bowman RM, Tomita T. Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery. 2012;70(1):40\u20137. https:\/\/doi.org\/10.1227\/NEU.0b013e31822ff0ed. (discussion 47\u20138).","journal-title":"Neurosurgery"},{"key":"1238_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jocn.2018.05.003","volume":"54","author":"S Mallick","year":"2018","unstructured":"Mallick S, Benson R, Melgandi W, Giridhar P, Rath GK. Grade II pleomorphic xanthoastrocytoma; a meta-analysis of data from previously reported 167 cases. J Clin Neurosci. 2018;54:57\u201362. https:\/\/doi.org\/10.1016\/j.jocn.2018.05.003.","journal-title":"J Clin Neurosci"},{"issue":"24","key":"1238_CR51","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/nejm199306173282401","volume":"328","author":"PK Duffner","year":"1993","unstructured":"Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328(24):1725\u201331. https:\/\/doi.org\/10.1056\/nejm199306173282401.","journal-title":"N Engl J Med"},{"issue":"5","key":"1238_CR52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/jco.1993.11.5.850","volume":"11","author":"RJ Packer","year":"1993","unstructured":"Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11(5):850\u20136. https:\/\/doi.org\/10.1200\/jco.1993.11.5.850.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1238_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1023\/a:1005736104205","volume":"32","author":"MD Prados","year":"1997","unstructured":"Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32(3):235\u201341. https:\/\/doi.org\/10.1023\/a:1005736104205.","journal-title":"J Neurooncol"},{"issue":"21","key":"1238_CR54","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/jco.2011.36.6054","volume":"30","author":"JL Ater","year":"2012","unstructured":"Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(21):2641\u20137. https:\/\/doi.org\/10.1200\/jco.2011.36.6054.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1238_CR55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/bf02072067","volume":"149","author":"R Brauner","year":"1990","unstructured":"Brauner R, Malandry F, Rappaport R, Zucker JM, Kalifa C, Pierre-Kahn A, et al. Growth and endocrine disorders in optic glioma. Eur J Pediatr. 1990;149(12):825\u20138. https:\/\/doi.org\/10.1007\/bf02072067.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"1238_CR56","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3171\/jns.1989.70.5.0707","volume":"70","author":"RJ Packer","year":"1989","unstructured":"Packer RJ, Sutton LN, Atkins TE, Radcliffe J, Bunin GR, D\u2019Angio G, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg. 1989;70(5):707\u201313. https:\/\/doi.org\/10.3171\/jns.1989.70.5.0707.","journal-title":"J Neurosurg"},{"issue":"16","key":"1238_CR57","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/jco.2005.03.8349","volume":"24","author":"S Sharif","year":"2006","unstructured":"Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570\u20135. https:\/\/doi.org\/10.1200\/jco.2005.03.8349.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1238_CR58","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ijrobp.2017.07.023","volume":"99","author":"DS Tsang","year":"2017","unstructured":"Tsang DS, Murphy ES, Merchant TE. Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys. 2017;99(3):642\u201351. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.07.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1238_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/a-0889-8256","volume":"231","author":"AK Gnekow","year":"2019","unstructured":"Gnekow AK, Kandels D, Tilburg CV, Azizi AA, Opocher E, Stokland T, et al. SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 2019;231(3):107\u201335. https:\/\/doi.org\/10.1055\/a-0889-8256.","journal-title":"Klin Padiatr"},{"issue":"29","key":"1238_CR60","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/jco.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol. 2020;38(29):3407\u201317. https:\/\/doi.org\/10.1200\/jco.19.02983.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1238_CR61","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1500925.","journal-title":"N Engl J Med"},{"issue":"3","key":"1238_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/s0360-3016(01)01705-9","volume":"51","author":"BJ Fisher","year":"2001","unstructured":"Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys. 2001;51(3):704\u201310. https:\/\/doi.org\/10.1016\/s0360-3016(01)01705-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"1238_CR63","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/jco.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol. 2023;41(33):5187\u201399. https:\/\/doi.org\/10.1200\/jco.23.01059.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1238_CR64","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3174\/ajnr.A5957","volume":"40","author":"PP Batchala","year":"2019","unstructured":"Batchala PP, Muttikkal TJE, Donahue JH, Patrie JT, Schiff D, Fadul CE, et al. Neuroimaging-based classification algorithm for predicting 1p\/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol. 2019;40(3):426\u201332. https:\/\/doi.org\/10.3174\/ajnr.A5957.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"1238_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00381-016-3262-4","volume":"33","author":"S Gaudino","year":"2017","unstructured":"Gaudino S, Martucci M, Russo R, Visconti E, Gangemi E, D\u2019Argento F, et al. MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma. Childs Nerv Syst. 2017;33(1):35\u201354. https:\/\/doi.org\/10.1007\/s00381-016-3262-4.","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"1238_CR66","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/s1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hern\u00e1iz Driever P, Bag AK, de Blank P, Kadom N, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21(6):e305\u201316. https:\/\/doi.org\/10.1016\/s1470-2045(20)30064-4.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1238_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.Ccr-23-1503","volume":"30","author":"MI Barbato","year":"2024","unstructured":"Barbato MI, Nashed J, Bradford D, Ren Y, Khasar S, Miller CP, et al. FDA approval summary: dabrafenib in combination with trametinib for BRAFV600E mutation-positive low-grade glioma. Clin Cancer Res. 2024;30(2):263\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1503.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1238_CR68","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML, Hara J, Plant-Fox A, Aerts I, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023;389(12):1108\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2303815.","journal-title":"N Engl J Med"},{"issue":"8","key":"1238_CR69","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.Ccr-24-3439","volume":"31","author":"S Singh","year":"2025","unstructured":"Singh S, Bradford D, Chatterjee S, Li X, Aungst SL, Skinner AM, et al. FDA approval summary: tovorafenib for relapsed or refractory BRAF-altered pediatric low-grade glioma. Clin Cancer Res. 2025;31(8):1383\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-3439.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1238_CR70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, et al. The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30(1):207\u201317. https:\/\/doi.org\/10.1038\/s41591-023-02668-y.","journal-title":"Nat Med"},{"issue":"12","key":"1238_CR71","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/jco.2011.34.5843","volume":"30","author":"E Bouffet","year":"2012","unstructured":"Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358\u201363. https:\/\/doi.org\/10.1200\/jco.2011.34.5843.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1238_CR72","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/2767-9764.Crc-24-0451","volume":"5","author":"S Rastogi","year":"2025","unstructured":"Rastogi S, Perino S, Lal-Nag M, Wang Y, Blackman SC, Venetsanakos E. Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or an NF1 loss-of-function mutation. Cancer Res Commun. 2025;5(4):668\u201379. https:\/\/doi.org\/10.1158\/2767-9764.Crc-24-0451.","journal-title":"Cancer Res Commun"},{"issue":"10","key":"1238_CR73","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","volume":"84","author":"YN Lamb","year":"2024","unstructured":"Lamb YN. Vorasidenib: first approval. Drugs. 2024;84(10):1325\u201331. https:\/\/doi.org\/10.1007\/s40265-024-02097-2.","journal-title":"Drugs"},{"issue":"3","key":"1238_CR74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","volume":"29","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023;29(3):615\u201322. https:\/\/doi.org\/10.1038\/s41591-022-02141-2.","journal-title":"Nat Med"},{"issue":"16","key":"1238_CR75","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.Ccr-21-0611","volume":"27","author":"IK Mellinghoff","year":"2021","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, et al. Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma: results of a first-in-human phase I trial. Clin Cancer Res. 2021;27(16):4491\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0611.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1238_CR76","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194.","journal-title":"N Engl J Med"},{"issue":"Supplement_8","key":"1238_CR77","doi-asserted-by":"publisher","first-page":"viii108","DOI":"10.1093\/neuonc\/noae165.0420","volume":"26","author":"IK Mellinghoff","year":"2024","unstructured":"Mellinghoff IK, van den Bent MJ, Touat M, Blumenthal DT, Peters KB, Ellingson BM, et al. CTNI-53. A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1\/2 mutation (INDIGO): updated efficacy results. Neuro Oncol. 2024;26(Supplement_8):viii108\u20139. https:\/\/doi.org\/10.1093\/neuonc\/noae165.0420.","journal-title":"Neuro Oncol"},{"issue":"15","key":"1238_CR78","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.Ccr-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, et al. FDA approval summary: selumetinib for plexiform neurofibroma. Clin Cancer Res. 2021;27(15):4142\u20136. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-5032.","journal-title":"Clin Cancer Res"},{"key":"1238_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf065","author":"J Fangusaro","year":"2025","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Lensing S, Ligon AH, Lindeman N, et al. A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4. Neuro Oncol. 2025. https:\/\/doi.org\/10.1093\/neuonc\/noaf065.","journal-title":"Neuro Oncol"},{"key":"1238_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02190-0","author":"SM Hoy","year":"2025","unstructured":"Hoy SM. Mirdametinib: first approval. Drugs. 2025. https:\/\/doi.org\/10.1007\/s40265-025-02190-0.","journal-title":"Drugs"},{"issue":"12","key":"1238_CR81","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Encorafenib and binimetinib: first global approvals. Drugs. 2018;78(12):1277\u201384. https:\/\/doi.org\/10.1007\/s40265-018-0963-x.","journal-title":"Drugs"},{"issue":"Supplement_1","key":"1238_CR82","doi-asserted-by":"publisher","first-page":"i191","DOI":"10.1093\/neuonc\/noac079.716","volume":"24","author":"N Robison","year":"2022","unstructured":"Robison N, Pauly J, Malvar J, Gardner S, Allen J, Margol A, et al. LTBK-04. Late breaking abstract: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study. Neuro Oncol. 2022;24(Supplement_1):i191\u20132. https:\/\/doi.org\/10.1093\/neuonc\/noac079.716.","journal-title":"Neuro Oncol"},{"issue":"2","key":"1238_CR83","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2159-8290.Cd-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):184\u201395. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1119.","journal-title":"Cancer Discov"},{"issue":"16_suppl","key":"1238_CR84","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.2022.40.16_suppl.3009","volume":"40","author":"KT Vo","year":"2022","unstructured":"Vo KT, Sabnis AJ, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, et al. Ulixertinib in patients with tumors with MAPK pathway alterations: results from NCI-COG pediatric MATCH trial arm J (APEC1621J). J Clin Oncol. 2022;40(16_suppl):3009. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.3009.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1238_CR85","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2023.41.16_suppl.3006","volume":"41","author":"MI De La Fuente","year":"2023","unstructured":"De La Fuente MI, Rodon Ahnert J, Yaeger R, Tsai FY-C, Janku F, Butowski NA, et al. Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: results from a phase 1\/2a study. J Clin Oncol. 2023;41(16_suppl):3006. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3006.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1238_CR86","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1158\/1078-0432.Ccr-21-4462","volume":"28","author":"SJ Casak","year":"2022","unstructured":"Casak SJ, Pradhan S, Fashoyin-Aje LA, Ren Y, Shen YL, Xu Y, et al. FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. Clin Cancer Res. 2022;28(13):2733\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4462.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1238_CR87","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/1078-0432.Ccr-18-3749","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res. 2019;25(11):3205\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3749.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"1238_CR88","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/jco.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398\u2013406. https:\/\/doi.org\/10.1200\/jco.19.03327.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1238_CR89","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/neuonc\/noac155","volume":"25","author":"A Natsume","year":"2023","unstructured":"Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, et al. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2023;25(2):326\u201336. https:\/\/doi.org\/10.1093\/neuonc\/noac155.","journal-title":"Neuro Oncol"},{"issue":"33","key":"1238_CR90","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1080\/14796694.2024.2383064","volume":"20","author":"SA Cain","year":"2024","unstructured":"Cain SA, Topp M, Rosenthal M, Tobler R, Freytag S, Best SA, et al. A perioperative study of safusidenib in patients with IDH1-mutated glioma. Future Oncol. 2024;20(33):2533\u201345. https:\/\/doi.org\/10.1080\/14796694.2024.2383064.","journal-title":"Future Oncol"},{"issue":"11","key":"1238_CR91","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Pamiparib: first approval. Drugs. 2021;81(11):1343\u20138. https:\/\/doi.org\/10.1007\/s40265-021-01552-8.","journal-title":"Drugs"},{"issue":"Supplement_5","key":"1238_CR92","doi-asserted-by":"publisher","first-page":"v84","DOI":"10.1093\/neuonc\/noad179.0323","volume":"25","author":"D Schiff","year":"2023","unstructured":"Schiff D, Bindra RS, Li J, Ye X, Ellingson B, Walbert T, et al. CTNI-41. Phase II and phase 0 results of ABTC 1801: a multi-arm clinical trial of the PARP inhibitor pamiparib with very low dose metronomic temozolomide in recurrent IDH mutant gliomas. Neuro Oncol. 2023;25(Supplement_5):v84. https:\/\/doi.org\/10.1093\/neuonc\/noad179.0323.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1238_CR93","doi-asserted-by":"publisher","first-page":"112283","DOI":"10.1016\/j.isci.2025.112283","volume":"28","author":"Y Pang","year":"2025","unstructured":"Pang Y, Li Q, Sergi Z, Yu G, Kim O, Lu P, et al. Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib. iScience. 2025;28(4):112283. https:\/\/doi.org\/10.1016\/j.isci.2025.112283.","journal-title":"iScience."},{"key":"1238_CR94","doi-asserted-by":"publisher","unstructured":"Kang C. Olutasidenib: first approval. Drugs. 2023;83(4):341\u2013346. https:\/\/doi.org\/10.1007\/s40265-023-01844-1.","DOI":"10.1007\/s40265-023-01844-1"},{"issue":"12","key":"1238_CR95","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.Ccr-20-4730","volume":"27","author":"J Wu","year":"2021","unstructured":"Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, et al. Phase I study of zotiraciclib in combination with temozolomide for patients with recurrent high-grade astrocytomas. Clin Cancer Res. 2021;27(12):3298\u2013306. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4730.","journal-title":"Clin Cancer Res"},{"key":"1238_CR96","doi-asserted-by":"publisher","unstructured":"de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib\/II trial. Neuro Oncol. 2023;25(1):146\u2013156. https:\/\/doi.org\/10.1093\/neuonc\/noac139.","DOI":"10.1093\/neuonc\/noac139"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01238-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:02:17Z","timestamp":1767646937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01238-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01238-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KBP serves on the scientific advisory board for AnHeart, Ono Pharmaceuticals, Rigel, and Servier Pharmaceuticals, and receives research funding from AnHeart, Novocure, NuVox, Nuvartion, Ono Pharmaceuticals, Sapience, and Servier Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KBP conceived and designed the work, completed the literature review and analysis, and prepared the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}